The RhizoBriva platform is a highly versatile technology, which allows for the production of complex, functionally active molecules (recombinant proteins and secondary metabolites), taking advantage of controlled and confined culture conditions in bioreactors, enabling a strong reproducibility.
Potential application areas: therapeutic, cosmetic, nutrition, diagnostic ...
Recombinant proteins are produced using a process combining the advantages of higher eukaryotic cells (efficient protein folding, competitive stability, activity and reproducibility compared to counterparts produced in mammalian cells) while being cost-effective (low capex and COGS). This process presents a lot of similarities with usual cell line cultures, making it possible to seamlessly apply the regulatory Guidelines usually followed for the manufacturing of culture cell lines
Since the secondary metabolites (stilbenes, alkaloids…), are usually obtained by direct extraction from plants grown in natural habitat or in greenhouses, several factors can alter their yield. Using the RhizoBriva platform, secondary non-GMO plant metabolites can be obtained with several advantages:
- quantities at least comparable to that of intact plants
- removal of all geopolitical, seasonal or climatic risks
- safer, animal/virus free, process not requiring any fungicide nor insecticide
- low environmental impact
Current internal program on lysosomal enzymes (within a European program (Pharmafactory-H2020) and on undisclosed proteins and secondary metabolites (programs developed for/with industrial partners)
+33 (0)322 092 830